The landscape of cardiovascular diagnostics has been jolted by a high-stakes legal confrontation as HeartFlow, a pioneer in artificial intelligence-powered cardiac imaging, filed a comprehensive lawsuit against its direct competitor, Cleerly. The complaint, lodged in a federal court in the Eastern District of Texas, marks a significant escalation in the battle for dominance within the multi-billion-dollar cardiac AI market. HeartFlow’s legal action alleges that Cleerly, a startup founded by a former HeartFlow consultant, built its business by infringing upon six key patents and misappropriating proprietary trade secrets and confidential business information.
The lawsuit describes the situation as "one of the most egregious examples of piracy in the medical technology industry," framing the dispute not merely as a disagreement over intellectual property, but as a systematic effort to replicate HeartFlow’s foundational innovations. As the healthcare industry increasingly shifts toward non-invasive diagnostic tools, the outcome of this litigation could redefine the competitive boundaries of medical AI and influence how proprietary algorithms are protected in the clinical space.
The Genesis of the Conflict: A Shared History
To understand the gravity of the allegations, one must look back at the origins of both companies. HeartFlow was established in 2010, the brainchild of a bioengineer and a vascular surgeon from Stanford University. The company’s primary innovation, the HeartFlow FFR-CT (Fractional Flow Reserve derived from Computed Tomography) Analysis, represented a paradigm shift in cardiology. By applying advanced AI and computational fluid dynamics to standard coronary CT scans, HeartFlow enabled physicians to visualize blood flow and identify significant blockages without the need for invasive cardiac catheterization. This technology effectively bridged the gap between anatomical imaging (what the heart looks like) and physiological assessment (how the heart functions).
In 2012, as HeartFlow was entering its most critical phase of research and development, it engaged Dr. James Min, a prominent cardiologist, as a consultant. According to the legal complaint, Dr. Min served in this capacity until 2017. During these five years—described by HeartFlow as its "most formative"—Min allegedly gained "intimate access" to the company’s internal diagnostic frameworks, confidential business strategies, and the underlying logic of its revolutionary cardiovascular technology.
The conflict reached a boiling point when Dr. Min founded Cleerly in 2017. HeartFlow alleges that while Min was still under contractual obligations to the company, he incorporated Cleerly and began developing a competing platform. While HeartFlow’s primary focus has been on blood flow dynamics (FFR-CT), Cleerly entered the market with an AI tool focused on quantifying coronary plaque and assessing long-term heart disease risk. However, HeartFlow contends that the methods Cleerly utilizes to segment coronary arteries and model vessel structures are direct infringements of its established intellectual property.
Detailed Allegations and Patent Infringement
The heart of the lawsuit centers on six specific patents held by HeartFlow. These patents cover the fundamental technological building blocks required to transform a two-dimensional CT scan into a sophisticated three-dimensional diagnostic model. Specifically, the patents involve:
- Automated Vessel Segmentation: The process by which AI identifies and "carves out" the coronary arteries from surrounding tissue in a digital image.
- Plaque Modeling: The methodology used to differentiate between various types of plaque (calcified vs. non-calcified) and how they constrict the vessel.
- Blood Flow Estimation: The complex mathematical modeling used to predict how physical blockages impact hemodynamic pressure.
- Vessel Structure Analysis: The algorithms that determine the geometry of the arterial tree, which is essential for accurate diagnostic simulation.
HeartFlow’s complaint asserts that Cleerly’s products, which also provide automated analyses of cardiac CT scans, could not have achieved their current level of sophistication without utilizing the specific processes patented by HeartFlow. The lawsuit further suggests that the timing of Cleerly’s product development, coinciding with Dr. Min’s departure from HeartFlow, indicates a direct transfer of proprietary knowledge.
In seeking both financial damages and a permanent injunction, HeartFlow is essentially attempting to bar Cleerly from selling or using any technology that utilizes these patented methods. If granted, such an injunction could effectively halt Cleerly’s operations in the United States, or force a massive overhaul of its software architecture.
Cleerly’s Defense and the Scientific Counter-Narrative
In response to the allegations, Dr. James Min and Cleerly have maintained a stance of firm denial. In a statement provided to the media, Dr. Min defended the originality of his company’s work, emphasizing that Cleerly’s technology is rooted in its own distinct clinical research and scientific publications.
"Cleerly has published landmark clinical science that has redefined how cardiovascular disease is understood and treated," Min stated. He argued that the company’s novel technologies provide physicians with "actionable insights" that are distinct from existing solutions. Cleerly’s defense likely rests on the distinction between "physiology" (HeartFlow’s focus) and "phenotyping" (Cleerly’s focus). Cleerly has positioned itself as a "plaque-first" company, arguing that understanding the composition and volume of plaque is more predictive of future heart attacks than simply measuring blood flow at a single point in time.
The legal battle will likely hinge on technical "claim construction" hearings, where the court will determine exactly what HeartFlow’s patents cover and whether Cleerly’s specific lines of code and algorithmic logic perform the same functions in the same way to achieve the same results.
The Economic Stakes: A Multi-Billion Dollar Frontier
The timing of this lawsuit is no coincidence. The market for cardiac imaging and related AI diagnostics is currently experiencing an era of unprecedented growth. According to the Medicare Payment Advisory Commission (MedPAC), diagnostic imaging consistently ranks among the highest-volume and highest-cost services in the American healthcare system. Within this category, Coronary CT Angiography (CCTA) is the fastest-growing segment.
Several factors are driving this expansion:
- Clinical Guidelines: Both the American College of Cardiology (ACC) and the American Heart Association (AHA) have recently updated their guidelines to recommend CCTA as a first-line test for patients with stable and acute chest pain.
- Reimbursement Pathways: HeartFlow successfully navigated the complex process of obtaining Category I CPT codes, ensuring that hospitals and clinicians are reimbursed for using their AI analysis. This established a financial blueprint that other companies, including Cleerly, are eager to follow.
- Volume Potential: Millions of patients undergo cardiac evaluations annually. As AI tools move from "experimental" to "standard of care," the potential for recurring revenue from software-as-a-service (SaaS) models in hospitals is immense.
Because the stakes are so high—involving billions of dollars in potential annual revenue—the battle over intellectual property is about more than just credit; it is about market control. If HeartFlow can prove that its patents are the "gatekeepers" for all AI-based coronary artery analysis, it could maintain a near-monopoly on the most lucrative segment of digital cardiology.
Industry Implications and Future Outlook
The legal fight between HeartFlow and Cleerly is being closely watched by venture capitalists, healthcare providers, and other medical technology firms. It serves as a cautionary tale regarding the "revolving door" of consultants and executives in the tech space. The "insider threat" narrative presented by HeartFlow highlights the vulnerability of medtech companies that rely on high-level academic and clinical consultants who may later become competitors.
Furthermore, this case could set a precedent for how "black box" AI algorithms are treated in patent law. Unlike a physical medical device, where infringement can be seen in a mechanical design, AI infringement often involves hidden layers of code and data processing. Proving that one AI "thinks" or "calculates" in the same way as another is a significant legal and technical challenge.
For healthcare providers, the lawsuit introduces an element of uncertainty. Hospitals that have integrated Cleerly’s platform into their workflows must now consider the risk of a potential court-ordered injunction that could disrupt their diagnostic capabilities. Conversely, a victory for Cleerly could embolden more startups to enter the space, potentially driving down costs through competition but also complicating the intellectual property landscape further.
As the case moves forward in the Texas federal court, the discovery phase will likely reveal internal communications and technical documentation that will shed light on the true origins of Cleerly’s platform. For now, the cardiac AI sector remains in a state of high tension, waiting to see if the "pioneer" of the industry can successfully defend its territory against the "protege" it once hosted. The resolution of this case will undoubtedly be a defining moment for the future of digital health and the protection of artificial intelligence in medicine.
